2 learning resources available for this topic
Asthma phenotyping involves classifying asthma based on clinical characteristics, inflammatory patterns, and molecular mechanisms to enable personalized treatment approaches. Biologic therapies target specific inflammatory pathways and are particularly effective for severe, uncontrolled asthma that doesn't respond adequately to conventional treatments.
Different asthma phenotypes exhibit distinct inflammatory profiles, with Type 2 (T2)-high asthma characterized by eosinophilic inflammation driven by IL-4, IL-5, and IL-13 cytokines, while T2-low asthma involves neutrophilic inflammation and different molecular pathways. Biologics work by specifically blocking key inflammatory mediators such as IgE, IL-5, IL-4/IL-13 receptors, or TSLP, thereby interrupting the cascade of allergic and eosinophilic inflammation.
Phenotyping guides clinicians in selecting appropriate biologic therapy based on biomarkers such as blood eosinophil counts, fractional exhaled nitric oxide (FeNO), IgE levels, and specific allergen sensitivities. This precision medicine approach improves treatment outcomes by matching patients with the most suitable biologic agent, reducing exacerbations and improving quality of life in severe asthma cases where traditional therapies have failed.